GLX351322

Cat. No.:	HY-100111
CAS No.:	835598-94-2
Molecular Formula:	$C_{21}H_{25}N_3O_5S$
Molecular Weight:	431.51
Target:	NADPH Oxidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 20 mg/mL (46.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3174 mL	11.5872 mL	23.1744 mL
	5 mM	0.4635 mL	2.3174 mL	4.6349 mL
	10 mM	0.2317 mL	1.1587 mL	2.3174 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC_{50} of 5 μM.

IC_{50} & Target

IC50: 5 μ M (NOX4, cell assay), 40 μM (NOX2, cell assay)[1]

In Vitro

GLX351322 is an inhibitor of NADPH oxidase 4, and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC_{50} of 5 μM. GLX351322 shows weak activity against NOX2 in hPBMC cells (IC_{50}, 40 μM).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GLX351322 (3.8 mg/kg/day, p.o.) ameliorates HFD-induced hyperglycemia in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Alzheimers Dement. 2020;16(Suppl. 3):e038198.
- J Cell Mol Med. 2020 Feb;24(4):2552-2565.
- Mol Cell Endocrinol. 2020 Dec 28;111144.
- Korean J Physiol Pharmacol. 2021 Mar 1;25(2):159-166.
- Research Square Preprint. 2020 Jul.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Anvari E, et al. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res. 2015;49(11):1308-18.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA